Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Sanofi
Thumbnail
August 12, 2022

Zantac burns big pharma

As Zantac litigation risk wipes $43bn off public company valuations are investors right to be worried?

Thumbnail
August 11, 2022

Cytokine players keep the faith

The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.

Article image
Vantage logo
August 11, 2022

Sanofi slumps as stagnation and litigation collide

Article image
Vantage logo
August 05, 2022

Sanofi keeps its eye on the China prize with Innovent deal

Article image
Vantage logo
July 28, 2022

Ex-US tolebrutinib expansion comes under the spotlight

Article image
Vantage logo
July 11, 2022

ISTH 2022 – Sanofi faces more fitusiran doubts

An investigator asks whether the haemophilia project, which has already been linked with toxicity concerns, should be given to elderly patients.

Article image
Vantage logo
July 04, 2022

US FDA approval tracker: June 2022

Article image
Vantage logo
June 30, 2022

Key data catalysts for the industry’s small players

Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.

Article image
Vantage logo
June 30, 2022

Sanofi gets more buyout blues

Article image
Vantage logo
June 28, 2022

Big pharma’s key third-quarter data

GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.

Article image
Vantage logo
June 27, 2022

Covid vaccine development could go Omicron-and-on

Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 15, 2022

Q2 Roundp Medtech Infographic

August 12, 2022

Q2 Roundup Pharma Infographic

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.